Medicenna Therapeutics announces expected upcoming milestones

Initial anti-tumor activity data from ABILITY’s fifth and sixth dose escalation cohorts in calendar Q3 2023. Commencement of the ABILITY study’s MDNA11 Phase 2 monotherapy arm expected in calendar Q3 2023. Clinical update from the ABILITY study’s MDNA11 Phase 2 monotherapy arm expected in calendar Q4 2023. Commencement of the MDNA11 plus pembrolizumab combination arm of the ABILITY study in calendar Q4 2023.